Marché mondial du sarcome de Kaposi – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et taille du marché du sarcome de Kaposi

Le marché mondial du traitement et de la gestion du sarcome de Kaposi (KS) est déterminé par plusieurs facteurs clés. L'incidence croissante du VIH/SIDA, qui constitue un facteur de risque majeur pour le développement du sarcome de Kaposi, continue de contribuer de manière significative à la croissance du marché. Selon l'American Cancer Society, le sarcome de Kaposi associé au SIDA survient à raison d'environ 6 cas par million d'habitants chaque année. Il est plus répandu chez les Afro-Américains que dans la population blanche aux États-Unis. Alors que les efforts de lutte contre le VIH/SIDA augmentent à l'échelle mondiale, en particulier dans les régions où les taux de prévalence sont élevés, la demande de traitements efficaces pour les affections associées telles que le KS devrait augmenter. En outre, les initiatives gouvernementales de soutien et les politiques de santé visant à améliorer l'accès aux services de santé et le taux de survie du sarcome de Kaposi stimulent encore davantage l'expansion du marché.

Français La taille du marché mondial du sarcome de Kaposi a été évaluée à 146,52 millions USD en 2023 et devrait atteindre 209,97 millions USD d'ici 2031, avec un TCAC de 4,60 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché       

Définition du marché

Le sarcome de Kaposi est un type de cancer qui se développe à partir des cellules qui tapissent les vaisseaux lymphatiques ou sanguins. Il apparaît généralement sous forme de tumeurs sur la peau ou les muqueuses et peut également affecter les organes internes. Le sarcome de Kaposi est causé par une infection par l'herpèsvirus humain 8 (HHV-8) et est le plus souvent observé chez les personnes dont le système immunitaire est affaibli, comme celles atteintes du VIH/SIDA.                    

Dynamique du marché du sarcome de Kaposi

Conducteurs

• Incidence élevée chez les patients atteints du VIH/SIDA  

Le lien étroit entre le sarcome de Kaposi et le VIH/SIDA influence considérablement la dynamique du marché, car les personnes vivant avec le VIH/SIDA présentent un risque accru de développer un sarcome de Kaposi en raison de leur système immunitaire affaibli. Par exemple, selon les statistiques publiées par le CDC en septembre 2022, environ 30 635 personnes aux États-Unis et dans ses territoires ont reçu un diagnostic de VIH en 2020. La prévalence du sarcome de Kaposi au VIH restant un problème de santé mondial, en particulier dans les régions où l'accès au traitement antirétroviral et aux ressources de santé est limité, la demande de traitements efficaces contre le sarcome de Kaposi continue d'augmenter. Les prestataires de soins de santé et les sociétés pharmaceutiques se concentrent sur le développement de thérapies ciblées et d'options de soins de soutien adaptées aux besoins uniques des patients séropositifs, stimulant ainsi l'innovation et l'investissement sur le marché du sarcome de Kaposi.   

• Initiatives gouvernementales de soutien aux traitements contre le sarcome de Kaposi  

Government-led initiatives aimed at enhancing HIV/AIDS awareness, facilitating early diagnosis, and improving access to healthcare services play a pivotal role in stimulating demand for Kaposi sarcoma treatments. Public health campaigns and policy frameworks prioritize HIV/AIDS prevention and management, thereby reducing the incidence of associated conditions such as Kaposi sarcoma. By fostering a supportive healthcare environment, governments contribute to the development and adoption of advanced diagnostic tools and therapeutic interventions for Kaposi sarcoma. These initiatives not only empower healthcare providers to deliver timely and comprehensive care but also encourage research and development investments in novel treatment modalities. Collaborative efforts between governments, healthcare organizations, and advocacy groups bolster market growth.

Opportunities

• Advancements in Treatment Options 

Ongoing research and development in chemotherapy, immunotherapy, and targeted therapies expand the range of treatment options available but also improve patient outcomes and quality of life. Chemotherapy regimens tailored to Kaposi sarcoma, along with immunotherapeutic approaches that enhance the immune system's ability to combat cancer cells, are showing promising results. Moreover, targeted therapies aimed at specific molecular targets associated with Kaposi sarcoma tumors offer the potential for more effective and less toxic treatments. Continued investment and innovation in these areas are crucial for addressing unmet medical needs, advancing the standard of care for Kaposi sarcoma patients globally, and creating significant opportunities in the Kaposi sarcoma market.   

• Growing Research and Development in Tools for Kaposi Sarcoma 

Increasing research funding and collaborative efforts among pharmaceutical companies, academic institutions, and healthcare organizations are driving the development of new therapeutic modalities and diagnostic biomarkers. Novel therapies, such as those targeting unique pathways in Kaposi sarcoma pathogenesis or utilizing advanced genetic testing to personalize treatment approaches, hold promise for enhancing efficacy and reducing side effects. The integration of innovative diagnostic technologies also supports early detection and monitoring of disease progression, contributing to improved patient management and clinical outcomes in the Kaposi sarcoma market.

Restraints/Challenges

• High Cost of Advanced Therapies     

The high cost of advanced therapies and supportive care for Kaposi sarcoma presents a formidable financial barrier to patient access, particularly in economically disadvantaged regions. The complex nature of managing Kaposi sarcoma, compounded by the need for prolonged treatment regimens and specialized medical interventions, contributes to escalating healthcare expenditures. Limited reimbursement options and out-of-pocket expenses further challenge affordability, hindering patient compliance and treatment outcomes.   

• Complex Disease Management of Immunocompromised Patients     

Managing Kaposi sarcoma in immunocompromised patients, particularly those living with HIV/AIDS, presents multifaceted clinical challenges that require specialized healthcare resources and expertise. The complexity of disease progression, variability in treatment responses, and potential for disease relapse necessitate comprehensive care strategies tailored to individual patient needs. Healthcare providers face challenges in early diagnosis, monitoring disease progression, and managing treatment-related complications, highlighting the importance of interdisciplinary collaboration and continuous medical education.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In February 2023, scientists at the UNC School of Medicine identified a protein facilitating disease causation and transmission by the Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV)
• In August 2022, Weill Cornell Medicine and Cornell Engineering created and tested a portable diagnostic device in clinical trials in Uganda to detect new instances of Kaposi sarcoma

Kaposi Sarcoma Market Scope

The market is segmented on the basis of type, treatment, diagnostics, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Epidemic (AIDS Associated) Kaposi Sarcoma
• Classic (Mediterranean) Kaposi Sarcoma
• Endemic (African) Kaposi Sarcoma
• Latrogenic (Transplant-Related) Kaposi Sarcoma

Treatment

• Highly Active Antiretroviral Therapy (HAART)
• Radiation Therapy
• Surgery
• Cryosurgery
• Chemotherapy
• Biological Therapy

Diagnostics

• Bronchoscopy
• Gastrointestinal Endoscopy
• Biopsy
• Others

End-Users

• Hospitals
• Homecare
• Specialty Centers
• Others

Kaposi Sarcoma Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, type, treatment, diagnostics, and end-user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to a robust presence of market players, and extensive research and development activities focused on Kaposi sarcoma treatment and diagnosis. In addition, the increasing prevalence of HIV and Kaposi sarcoma further bolstered regional market growth.      

Asia-Pacific is expected to witness significant growth during the forecast period due to a significant increase in the prevalence of organ transplantation and related therapeutic interventions across the region. This surge is driven by advancements in medical technology, improved healthcare infrastructure, and rising awareness about the benefits of organ donation and transplantation.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Kaposi Sarcoma Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)

SKU-57394